AstraZeneca has bumped up its stake in US biotech Moderna, which is pioneering the development of a new class of drugs made of messenger RNA, to nine percent.
The UK-listed group said it is investing a further $140 million to increase its equity interest in the company, adding to its previous stake garnered through a collaboration agreement signed back in March 2013.
The parties initially hooked up to develop medicines for cardiovascular, metabolic and renal diseases, as well as oncology, and subsequently signed another agreement in January this year solely focused on the development of cancer therapies.
The companies coupling AstraZeneca group MedImmune’s protein engineering and cancer biology expertise with Moderna’s technology platform in the hope of developing new mRNA-based therapies.
These enable the body to produce therapeutic protein in vivo, and thus potentially offer a new treatment approach for a wide range of diseases.
By Selina McKee
Source: Pharma Times
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.